PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
Julie Delyon(Inserm), Nicolas Dumaz(Inserm)
Cited by 4
Related Papers
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma
|Oncotarget|2015|33
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
|Cancers|2020|21
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
|Clinical Cancer Research|2021|19
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
|Biomedicines|2021|15